Labcorp Holdings Inc. (0JSY.L)
| Previous close | 209.78 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,534 |
| Market cap | 205.305M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 0.10 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia screening test to be performed between 11 and 14 weeks gestation to determine the risk of developing preeclampsia before 34 weeks of pregnancy. It is the only test of its kind available in the United States and is relevant for all pregnant individuals, including those with a low- to average-risk for preeclampsia or first-time pregnancies.
- PR Newswire
Labcorp to Webcast Its Annual Meeting of Shareholders
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 14 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations website. An archived replay of the webcast will be available for one year.
- PR Newswire
Invitae Receives Court Approval for Sale to Labcorp
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical genetics company, announced today that the United States Bankruptcy Court has approved the previously announced bid by Labcorp to acquire assets of Invitae.
